FDA ODACTRA label update (06/2026): dizziness and rash warnings

On June 12, 2026, the FDA approved an update to the ODACTRA label. The change adds “Nervous system disorders: dizziness” and “rash” to the 6.2 Postmarketing Experience section.

This isn’t a new diagnosis or a new treatment. It’s a safety-label update meant to improve clarity about symptoms that may be reported during real-world use—especially symptoms that can occur during serious allergic reactions.

What the FDA updated on June 12, 2026

In the June 12, 2026 supplement approval letter, FDA states it approved updating the package insert to include the terms “Nervous system disorders: dizziness” and “rash” in the 6.2 Postmarketing Experience section.

Quick context: what ODACTRA is (and what it’s for)

ODACTRA is a sublingual immunotherapy (allergen tablet) for house dust mite–induced allergic rhinitis, with or without conjunctivitis, confirmed by allergy testing. ODACTRA is approved for people ages 5 through 65.

It is not meant to provide immediate relief of allergy symptoms.

Safety first: who should not use ODACTRA

According to the FDA-approved prescribing information, ODACTRA is contraindicated in people with:

Severe, unstable, or uncontrolled asthma
A history of any severe systemic allergic reaction or any severe local reaction after sublingual allergen immunotherapy
A history of eosinophilic esophagitis
Hypersensitivity to any inactive ingredients in the product

The label also stresses that the first dose must be given in a healthcare setting, with observation for at least 30 minutes.

Symptoms to watch for: dizziness and rash

Because FDA added “dizziness” and “rash” to postmarketing adverse-reaction wording, patients and caregivers should treat these as part of the broader list of possible signs of a severe allergic reaction.

The ODACTRA label describes severe reactions as potentially involving more than one body system and may include symptoms such as:

Dizziness (and fainting/syncope)
Rash and itching (pruritus)
Breathing symptoms (for example, wheezing or shortness of breath)
Circulation symptoms (such as low blood pressure or feeling faint)
Swelling affecting skin or mucosal areas (for example, lips/face/throat)

When to get emergency help

If symptoms suggest anaphylaxis (a life-threatening allergic reaction), seek emergency care right away.

CDC guidance notes that anaphylaxis can involve symptoms across multiple body systems, including dizziness and skin/mucosal symptoms such as generalized hives or swelling of lips, face, or throat.

The ODACTRA label’s boxed warning also directs that prescribers prescribe epinephrine, train patients/guardians on how to use it, and instruct them to seek immediate medical care after using epinephrine.

Other “stop and call” situations (beyond dizziness and rash)

Along with the new label wording, ODACTRA has additional safety instructions for when to pause and contact a clinician:

Oral inflammation or wounds: stop ODACTRA to allow complete healing of the oral cavity (and contact a healthcare professional if symptoms persist or worsen).
Possible eosinophilic esophagitis (EoE): discontinue ODACTRA and contact a clinician if severe or persistent gastroesophageal symptoms occur, including dysphagia (trouble swallowing) or chest pain.
Asthma flare: withhold ODACTRA during an acute asthma exacerbation, and re-evaluate if asthma exacerbations recur.

Practical takeaway: dizziness, rash, breathing trouble, swelling, fainting, or worsening reactions should be treated as urgent and consistent with severe allergic reaction guidance.

Evidence context: what research says about SLIT

For allergic rhinitis, systematic reviews (including Cochrane evidence summaries) generally find that sublingual immunotherapy can improve symptoms and reduce medication needs compared with placebo. At the same time, clinical trials have strict participant selection and may not capture very rare events—one reason postmarketing label updates matter.

What readers can do today

Check your ODACTRA label (or ask your pharmacist/clinician whether your package insert reflects the revised June 2026 wording).
Confirm your risk factors with a clinician—especially asthma control status and any history of eosinophilic esophagitis or severe reactions.
Know your emergency steps (including having epinephrine if prescribed and understanding when to call emergency services).
Use your “stop-and-call” checklist: severe allergic reaction symptoms (including dizziness/rash), oral wounds/inflammation, and severe or persistent swallowing/chest symptoms.
Report new symptoms to your healthcare team so they can decide whether they fit expected side effects or require prompt evaluation.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.